Response Genetics, Inc.  

(Public, NASDAQ:RGDX)   Watch this stock  
Find more results for Sam Chawla�
0.710
+0.010 (1.43%)
Oct 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.69 - 0.78
52 week 0.51 - 2.22
Open 0.76
Vol / Avg. 50,393.00/103,842.00
Mkt cap 25.17M
P/E     -
Div/yield     -
EPS -0.64
Shares 38.73M
Beta 0.68
Inst. own 44%
Aug 14, 2014
Q2 2014 Response Genetics Inc Earnings Call
Aug 14, 2014
Q2 2014 Response Genetics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -73.32% -40.50%
Operating margin -72.58% -40.13%
EBITD margin - -36.93%
Return on average assets -94.73% -46.30%
Return on average equity -338.06% -307.49%
Employees 109 -
CDP Score - -

Address

6th Floor, 1640 Marengo St.
LOS ANGELES, CA 90033
United States - Map
+1-323-2243900 (Phone)
+1-323-2243096 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Response Genetics, Inc. is a life sciences company engaged in the research and development of clinical diagnostic tests for cancer. The Company�s technologies enable it to reliably and consistently extract ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) from tumor specimens that are stored as formalin-fixed and paraffin-embedded (FFPE) specimens and thereby to analyze genetic information contained in these tissues. The Company�s technologies also enable us to use the FFPE patient biopsies for the development of diagnostic tests. The Company provide tests for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric and gastroesophageal cancer (GE), melanoma and thyroid cancer, and breast cancer patients� tumor tissue specimens through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid and ResponseDX: Breast test.

Officers and directors

Thomas A. Bologna Chairman of the Board, Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
Kevin R. Harris Chief Financial Officer, Vice President
Age: 45
Bio & Compensation  - Reuters
Stephanie H. Astrow Ph.D. Vice President - Research & Development
Age: 52
Bio & Compensation  - Reuters
Adanech Getachew General Counsel
Age: 37
Bio & Compensation  - Reuters
Kirk K. Calhoun Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Michael Serruya Director
Age: 49
Bio & Compensation  - Reuters
Sam Chawla Independent Director
Age: 39
Bio & Compensation  - Reuters
David R. Schreiber Independent Director
Bio & Compensation  - Reuters
Richard A. Van den Broek Independent Director
Age: 48
Bio & Compensation  - Reuters